This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Argiris, A. Articles by Forastiere, A. A. Search for Related Content PubMed PubMed Citation Articles by Argiris, A. Articles by Forastiere, A. A. Social Bookmarking                            What's this?

Outcome of Elderly Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cisplatin-Based Chemotherapy

From the Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN; Fox Chase Cancer Center, Philadelphia, PA; and Johns Hopkins Oncology Center, Baltimore, MD

Address reprint requests to Athanassios Argiris, MD, 676 North St Clair, Suite 850, Division of Hematology-Oncology, Northwestern University, the Feinberg School of Medicine, Chicago, IL 60611; e-mail: a-argiris{at}northwestern.edu.

PURPOSE: To evaluate the outcome of elderly patients with head and neck cancer undergoing palliative chemotherapy.

PATIENTS AND METHODS: We analyzed combined data from two mature phase III randomized trials conducted by the Eastern Cooperative Oncology Group (ECOG; trial E1393, which compared cisplatin plus paclitaxel at two dose levels, and trial E1395, which compared cisplatin plus fluorouracil to cisplatin plus paclitaxel) to evaluate the toxicity, objective response rates, and survival of patients 70 years or older versus their younger counterparts. All patients had previously untreated recurrent or metastatic squamous cell carcinoma of the head and neck and ECOG performance status 0 or 1.

RESULTS: Fifty-three elderly patients were enrolled from a total of 399 eligible participants (13%). Elderly patients had similar objective response rates (28% v 33%) and median time to progression (5.25 v 4.8 months) compared with younger patients. The median survival was 5.3 v 8 months (Wilcoxon P = .06; log-rank P = .17) and the 1-year survival 26% v 33% for elderly and younger patients, respectively. Elderly patients had a significantly higher incidence of severe nephrotoxicity, diarrhea, and thrombocytopenia. A higher rate of toxic deaths was noted in the elderly but did not reach statistical significance (13% v 8%; P = .29).

CONCLUSION: Elderly patients were underrepresented in these studies. Fit elderly patients with recurrent or metastatic head and neck cancer sustained increased toxicities with cisplatin-based doublets but had comparable survival outcomes compared with younger patients. Strategies to ameliorate toxicities should be pursued in the elderly.

This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair).

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. De Santis, J. Bellmunt, G. Mead, J. M. Kerst, M. Leahy, P. Maroto, I. Skoneczna, S. Marreaud, R. de Wit, and R. Sylvester Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy: Phase II--Results of EORTC Study 30986 J. Clin. Oncol., November 20, 2009; 27(33): 5634 - 5639. [Abstract] [Full Text] [PDF]

				K. K. Ang Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes Oncologist, August 1, 2008; 13(8): 899 - 910. [Abstract] [Full Text] [PDF]

				C. E. Senkal, S. Ponnusamy, M. J. Rossi, K. Sundararaj, Z. Szulc, J. Bielawski, A. Bielawska, M. Meyer, B. Cobanoglu, S. Koybasi, et al. Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1188 - 1199. [Abstract] [Full Text] [PDF]

				S. M. Lichtman, D. Hollis, A. A. Miller, G. L. Rosner, C. A. Rhoades, E. P. Lester, F. Millard, J. Byrd, S. A. Cullinan, D. M. Rosen, et al. Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762) J. Clin. Oncol., April 20, 2006; 24(12): 1846 - 1851. [Abstract] [Full Text] [PDF]

				T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]

				A. Bamias, E. Efstathiou, L. A. Moulopoulos, D. Gika, G. Hamilos, M. P. Zorzou, C. Kakoyiannis, E. Kastritis, G. Bozas, C. Papadimitriou, et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy Ann. Onc., February 1, 2005; 16(2): 307 - 313. [Abstract] [Full Text] [PDF]